Leukopenia in Kidney Transplant Patients With the Association of Valganciclovir and Mycophenolate Mofetil

Transplantation Proceedings

Volumn 40, Issue 3, 2008, Pages 752-754

  Brum, S ^a   Nolasco, F ^a   Sousa, J ^a   Ferreira, A ^a   Possante, M ^a   Pinto, J R ^a   Barroso, E ^a   Santos, J R ^a  

^a HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOPENIA; MYCOPHENOLIC ACID; NEUTROPENIA; POSTOPERATIVE COMPLICATIONS;

EID: 42949143827     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.02.048     Document Type: Article

References (15)

1. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741
2. Sagedel S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66 (2004) 329
3. Guidelines of the American Society of Transplantation. Cytomegalovirus. Am J Transplant 4 suppl 10 (2004) 51
4. Pescovitz M.D., Rabkin, Merion R.M., et al. Valgancyclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44 (2000) 2811
5. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valgancyclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611
6. Akalin E., Sehgal V., Ames S., et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3 (2003) 731
7. Gabardi S., Magee C.C., Baroletti S.A., et al. Efficacy and safety of low dose valgancyclovir for prevention of cytomegalovirus disease in renal transplants recipients: a single-center, retrospective analysis. Pharmacotherapy 24 (2004) 1323
8. Keven K., Basu A., Tan H.P., et al. Cytomegalovirus prophylaxis using oral ganciclovir or valgancyclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 36 (2004) 3107
9. Weng F.L., Patel A., Wanchoo R., et al. Oral ganciclovir versus low-dose valgancyclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 83 (2007) 290
10. Preiksaitis J.K., Brennan D.C., Fishman J., et al. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5 (2005) 218
11. Pedroche C.D., Lumbreras C., Juan R., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipient. Transplantation 82 (2006) 30
12. Rerolle J., Szelag J., and Meur Y. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transplant 22 (2007) 671
13. Chen I., Chang H., Hsu C., et al. Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients. Circ J 71 (2007) 968
14. Pescovitz M. Is low dose valganciclovir the same as appropriate-dose valganciclovir. Transplantation 84 (2007) 126
15. Chamberlain C., Mannon R., Penzac S., et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 6 suppl 2 (2006) 266